Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-Based Chemotherapy After Developing Resistance to the First-Line Gefitinib Treatment
OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s100164
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2016
Authors
Publisher
Informa UK Limited